Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A proprietary, personalized autologous synthetic cancer vaccine composed of patient-specific synthetic cancer neo-epitopes complexed with heat shock protein 70 (HSP 70; HSP70), with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-HSP70 peptide cancer vaccine AGEN2017, the HSPs present the neoantigens to antigen presenting cells (APCs) and help elicit a potent neoantigen-specific T-cell-based anti-tumor immune response, thereby killing the neoantigen-expressing cancer cells. HSP70 is able to the transport the neo-epitopes, activate APCs and enhance the T-cell-mediated immune response.

**Synonyms:** - AGEN 2017 - AGEN-2017 - AGEN2017 - ASV - ASV AGEN2017 - AutoSynVax - AutoSynVax AGEN2017 - AutoSynVax Vaccine - Autologous Cancer Vaccine AGEN2017 - Neoantigen Vaccine AGEN2017